These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25770296)

  • 1. Pharmacogenomic modeling in pancreatic cancer—response.
    Yu KH
    Clin Cancer Res; 2015 Mar; 21(6):1498. PubMed ID: 25770296
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenomic modeling in pancreatic cancer—letter.
    Avan A; Avan A; Maftouh M; Mobarhan MG; Gholamin S
    Clin Cancer Res; 2015 Mar; 21(6):1497. PubMed ID: 25770295
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer.
    Yu KH; Ricigliano M; Hidalgo M; Abou-Alfa GK; Lowery MA; Saltz LB; Crotty JF; Gary K; Cooper B; Lapidus R; Sadowska M; O'Reilly EM
    Clin Cancer Res; 2014 Oct; 20(20):5281-9. PubMed ID: 25107917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pancreatic cancer: a major challenge in oncology].
    Fölsch UR; Schäfer H
    Med Klin (Munich); 2004 Apr; 99(4):183-4. PubMed ID: 15085287
    [No Abstract]   [Full Text] [Related]  

  • 5. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
    Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
    Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
    El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
    Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic, pharmacogenomic testing rapidly gaining acceptance.
    Morrow T
    Manag Care; 2004 Nov; 13(11):54-5. PubMed ID: 15595404
    [No Abstract]   [Full Text] [Related]  

  • 9. Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC).
    Aieta M; Facchinetti A; De Faveri S; Manicone M; Tartarone A; Possidente L; Lerose R; Mambella G; Calderone G; Zamarchi R; Rossi E
    Clin Lung Cancer; 2016 Sep; 17(5):e173-e177. PubMed ID: 27397482
    [No Abstract]   [Full Text] [Related]  

  • 10. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors.
    Gilbert JA; Lloyd RV; Ames MM
    N Engl J Med; 2005 Jul; 353(2):209-10. PubMed ID: 16014895
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy.
    Kang SP; Saif MW
    JOP; 2008 May; 9(3):251-66. PubMed ID: 18469437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.
    Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K
    Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment.
    Fitzgerald TL; McCubrey JA
    Adv Biol Regul; 2014 Sep; 56():45-50. PubMed ID: 24925031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of cugbp2 increases response of pancreatic cancer cells to chemotherapy.
    Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Dauksa A; Paskauskas S; Gulbinas A; Dambrauskas Z
    Langenbecks Arch Surg; 2016 Feb; 401(1):99-111. PubMed ID: 26691217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
    Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
    [No Abstract]   [Full Text] [Related]  

  • 16. Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation.
    Raj D; Aicher A; Heeschen C
    Stem Cells; 2015 Oct; 33(10):2893-902. PubMed ID: 26202953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer complexity slows quest for cure.
    Check Hayden E
    Nature; 2008 Sep; 455(7210):148. PubMed ID: 18784686
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate cancer: Wnt signalling induces resistance.
    Sidaway P
    Nat Rev Urol; 2015 Nov; 12(11):597. PubMed ID: 26439505
    [No Abstract]   [Full Text] [Related]  

  • 19. CANCER. Cancer therapies that are gone with the Wnt.
    Nanus DM; Giannakakou P
    Science; 2015 Sep; 349(6254):1283-4. PubMed ID: 26383936
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Merika E; Syrigos KN; Saif MW
    JOP; 2010 Jul; 11(4):328-30. PubMed ID: 20601804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.